PROSPECTIVE EVALUATION OF EFFICACY, SAFETY AND PATIENT SATISFACTION IN ENDOSCOPIC PROCEDURES WITH MODERATE SEDATION BY GASTROENTEROLOGISTS (GISED)

Luis Correia

UEG Week Copenhagen 2023 Poster

October 15, 2023

A prospective study of 264 patients undergoing endoscopy with gastroenterologist-administered moderate sedation using midazolam and pethidine found 82.5% patient satisfaction, 8% adverse events (mostly mild), and 82% willingness to repeat under the same conditions.

KEY POINTS

- Among 309 endoscopic procedures (28% gastroscopies, 72% colonoscopies) using midazolam (median 3.0-5.0 mg) and pethidine (median 25 mg), adverse events occurred in 8% of cases, predominantly mild hypotension or transient hypoxemia managed with oxygen; one patient required 24-hour hospitalization for atrial fibrillation.
- Patient satisfaction was high with 82.5% reporting at least satisfaction, 53% experiencing no pain, and 82% willing to repeat the procedure under the same conditions, though 72% remembered the procedure start and 56% remembered being awake during it.
- The sedation target of Ramsay score 3-4 was achieved in 44% of patients, and the protocol midazolam induction dose (0.05 mg/kg) was met in 59% of cases.
- The authors conclude that moderate sedation by gastroenterologists is safe and effective for low-risk procedures in ASA I-III patients, particularly where non-anaesthesiologist propofol administration is unavailable, and suggest that adherence to midazolam dosing protocols is important for patient satisfaction.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/25d2a41c-743d-11ee-acd9-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.